Andrea McNatty

Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer

T. Ho, B. Costello, A. Bryce, 2021, Prostate Cancer and Prostatic Diseases.

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

N. Agarwal, E. Antonarakis, C. Sternberg, 2020, JCO precision oncology.

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

E. Antonarakis, A. Bryce, Heather H. Cheng, 2019, European urology.

Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.

O. Sartor, J. Moslehi, D. Cope, 2020, Urologic oncology.

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer

C. Logothetis, A. Hussain, D. Cope, 2020, Prostate Cancer and Prostatic Diseases.

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

N. Agarwal, E. Antonarakis, C. Sternberg, 2019, Annals of Oncology.

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy

Farah Raheem, Vishal Shah, Henry Ofori, 2023, Biomedicines.